EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieOpen Access · CC BY 4.0

A dual-center analysis of conservative versus liberal glycoprotein IIb–IIIa antagonist strategies in the treatment of ST-elevation myocardial infarction

Kashi Callichurn, Philippe Simard, Corrado De Marco, Payman Jamali, Yacine Saada, Alexis Matteau, Érick Schampaert, Samer Mansour, Raja Hatem, Brian J Potter

Scientific Reports · 01.07.2024 · 14 (1)

DOI: 10.1038/s41598-024-64652-x ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Scientific Reports, online erschienen am 01.07.2024. Verfasst von Kashi Callichurn und 9 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, McGill University, Montreal, QC, Canada. Hauptthemen laut MEDLINE: Platelet Glycoprotein GPIIb-IIIa Complex, ST Elevation Myocardial Infarction, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While the efficacy of GpIIb–IIIa-inhibitors during primary PCI (pPCI) for ST-elevated myocardial infarction (STEMI) has previously been demonstrated, its ongoing role and safety in combination with newer P2Y12-inhibitors is unclear. We therefore sought to compare outcomes between two centers with divergent approaches to the use of GpIIbIIIa antagonists in pPCI. We performed a retrospective chart review of all-comer STEMI patients treated with pPCI at two high-volume Montreal academic tertiary care centers. One center tended to use GpIIb–IIIa-inhibitors up-front in a large proportion of patients (liberal strategy) and the other preferring a bail-out approach (conservative strategy). Baseline patient characteristics and procedural data were compared between the two groups. The main efficacy outcome was rate of no-reflow/slow-reflow and the main safety outcome was BARC ≥ 2 bleeding events. A total of 459 patients were included, of whom 167 (36.5%) were exposed to a GpIIb–IIIa-antagonist. There was a significant overall difference in use of GpIIb–IIIa-antagonist between the two centers (60.5% vs. 16.1%, p < 0.01). Rate of no-reflow/slow-reflow was similar between groups (2.6% vs. 1.4%, p = 0.22). In-hospital rates of unplanned revascularization, stroke and death were also not different between groups. Use of a liberal GpIIb-–IIIa-antagonist strategy was however associated with a higher risk of bleeding (OR 3.16, 95% CI 1.57–6.37, p < 0.01), which persisted after adjustment for covariables (adjusted OR 2.85, 95% CI 1.40–5.81, p < 0.01). In this contemporary retrospective cohort, a conservative, bail-out only GpIIb-–IIIa-antagonist strategy was associated with a lower incidence of clinically relevant bleeding without any signal for an increase in no-reflow/slow-reflow or ischemic clinical events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Platelet Glycoprotein GPIIb-IIIa ComplexST Elevation Myocardial InfarctionPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsHumansMaleFemaleMiddle AgedAgedRetrospective StudiesTreatment OutcomeHemorrhage

Substanzen

Platelet Glycoprotein GPIIb-IIIa ComplexPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Faculty of Medicine, McGill University, Montreal, QC, Canada.
  • Faculty of Medicine, Université de Montréal, Montreal, QC, Canada.
  • Department of Medicine, Division of Cardiology, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada.
  • CHUM Research Center (CRCHUM), Montreal, QC, Canada.
  • Department of Medicine, Division of Cardiology, Hôpital du Sacré-Cœur de Montréal, Montreal, QC, Canada.
  • Faculty of Medicine, McGill University, Montreal, QC, Canada. brian.potter@umontreal.ca.

Zitieren

APA

Callichurn, K., Simard, P., De Marco, C., Jamali, P., Saada, Y., Matteau, A., Schampaert, É., Mansour, S., Hatem, R., & Potter, B. J. (2024). A dual-center analysis of conservative versus liberal glycoprotein IIb–IIIa antagonist strategies in the treatment of ST-elevation myocardial infarction. Scientific Reports, 14(1). https://doi.org/10.1038/s41598-024-64652-x

Vancouver

Callichurn K, Simard P, De Marco C, Jamali P, Saada Y, Matteau A, et al. A dual-center analysis of conservative versus liberal glycoprotein IIb–IIIa antagonist strategies in the treatment of ST-elevation myocardial infarction. Scientific Reports. 2024;14(1). doi:10.1038/s41598-024-64652-x

BibTeX
@article{Callichurn2024,
  author = {Callichurn, Kashi and Simard, Philippe and De Marco, Corrado and Jamali, Payman and Saada, Yacine and Matteau, Alexis and Schampaert, Érick and Mansour, Samer and Hatem, Raja and Potter, Brian J},
  title = {A dual-center analysis of conservative versus liberal glycoprotein IIb–IIIa antagonist strategies in the treatment of ST-elevation myocardial infarction},
  journal = {Scientific Reports},
  year = {2024},
  volume = {14},
  number = {1},
  doi = {10.1038/s41598-024-64652-x}
}
Kostenlos starten →